Nicotinic Acetylcholine Receptor gamma/CHRNG CRISPR/Cas9 KO Plasmid (m): sc-418961

Overview

Chrng encodes the gamma subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated cation channel that assembles with other muscle-type nAChR subunits to mediate acetylcholine-dependent depolarization at the neuromuscular junction. In mouse development, CHRNG is a key component of the fetal receptor complex and supports synaptogenesis, activity-dependent maturation of skeletal muscle, and excitability control through rapid ion flux and downstream Ca2+-linked signaling. Altered CHRNG expression or subunit composition can perturb neuromuscular transmission and myofiber differentiation programs, providing a mechanistic entry point to study congenital and developmental neuromuscular phenotypes. This gene is therefore relevant to pathways governing motor endplate formation, excitation–contraction coupling, and muscle developmental timing.

Nicotinic Acetylcholine Receptor gamma/CHRNG CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Chrng gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Chrng together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Chrng open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Nicotinic Acetylcholine Receptor gamma/CHRNG protein expression.

This CRISPR knockout system enables efficient generation of Chrng-deficient cell models for investigation of Nicotinic Acetylcholine Receptor gamma/CHRNG signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting Chrng exon(s) critical for Nicotinic Acetylcholine Receptor gamma/CHRNG function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple Chrng genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by Nicotinic Acetylcholine Receptor gamma/CHRNG CRISPR/Cas9 KO Plasmid (m) and Nicotinic Acetylcholine Receptor gamma/CHRNG CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Chrng locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by Nicotinic Acetylcholine Receptor gamma/CHRNG HDR Plasmid (m) and Nicotinic Acetylcholine Receptor gamma/CHRNG HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Chrng homology arms to support homology-directed repair at defined Chrng target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.